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The self-adtninistered psoriasis area and severity in-
dex (SAP ASI) is a structured instrument for measuring 
the severity of psoriasis. This study examines the valid-
ity, reliability, and responsiveness of the SAPASI. 
Trained personnel performed a psoriasis area and se-
verity index (P ASI) assessment on the same day a 
SAPASI was obtained from 80 subjects. The validity of 
the SAP ASI was demonstrated using the P ASI as the 
standard (r2 = 0.59, P = 0.0001). Significant correlations 
w ere found between SAP ASI and P ASI for body surface 
area (r = 0.62-0.75), erythema (r = 0.39), induration 
(r = 0.24) and scale (r = 0.38). Test-retest reliability was 
C lin ica l in ves tig ators fi'equently m easure the severity of psoriasis with the p sori asis a rea and severity index (PASI). Since its d eve lo pme nt in 1978 [5] , th is instrum cnt has b een u sed throug h o ut the wodd b y c1irlical investigators [1,2,7,9]. Because PASI m ea-
sures are resource inten sive and require trained p e rsonne l, its 
applica tio n to la rge- scale research o n psoriasis is limite d. We 
previo u sly reporte d o n the development of a structured PASr-like 
instrument, th e self- administered PASI (SAP ASI) , that a llows pa-
tients to assess accurate ly the severity of psoriasis [3]. Since our 
original report, we h ave continue d to evaluate the validi ty of this 
cunimetric instrume nt. Th is report o utlin es steps our g roup has 
taken to assess the c riterion validity , re liab ili ty , and respon siven ess 
of the SAPASI. C riterio n va lidi ty refe rs to h ow th e m easure 
compares with th e "gold standard" [8]. R e liabili ty is the extent to 
which a m easure y ie lds the sam e score each time, a ll other things 
bein g equ al. R esp o nsi ven ess is the abili ty of a m easure to re fl ect 
und e rl ying c hange. 
MATEIUALS AND METHODS 
Participants in tlllS study were patients presenting to the Bowman Gray 
School ofMcdicinc ofWakc Forest University Psoriasis and Skin Treatmcnt 
Centcr who had received the diagnosis of psoriasis vulgaris. New patients, 
patients returning for follow up visits. and patients returning for treatments 
were included in the study po pulation. A one-page instrumcnt [3] (SAPAS I) 
consisting of two parts was employed to measurc the severi ty of psoriasis. 
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assessed in 19 subjects with repeated evaluations within 
2 d. Correlations between the first and second SAPASI 
scores (r = 0.82) were highly significant (p = 0.0001). 
Inter-rater reliability of SAP AS I body surface area mea-
surements among five raters was very high (intraclass 
correlation coefficient R = 0.953). The SAPASI was 
responsive to changes in severity over time as demon-
strated by correlation with changes in PASI scores (r = 
0.63, P = 0.0002). We conclude that this structured 
patient self-report instrument facilitates quantitative 
assessment of psoriasis. Key IVOI,ds: PASIlepide",iologyl 
J1alidity. ] Invest D ermatol 106:183-186, 1996 
T he instrunlcnt was given to the patients without any infornlaoo n or 
guidance bcyond the instructions on thc one-pagc instrument. T hc patients 
re ce ived no training in nl casure lllcnt of psoriasis and no training in th e usc 
of thc SAPAS) instrument itself. Subjects rated the colo r, induration. and 
scalincss of an "average" psoriatic Icsion with three modified visual analog 
sca les [3J. T hese sca les consist ofa line on w hich the subj ects make a ma rk 
to signi fy the severity of the psoriasis. Anchors arc prcsent at inte rval s a long 
the lines as guides as previously described Pl. As in thc original PAS] score 
[5], thc SAPAS I weights the involvcmcnt of thc head. uppcr cxtremitics, 
trunk. and legs as 10.20.30. and 40'Yo ofthc tota l body surfacc arca (13SA). 
re spcc tively. To cstimatc the surf.,ce area involved, a line-drawing si lhou-
ettc of the front and back of a body is presentcd to patients and thcy arc 
instructcd to shade in the areas currcntly affected by psoriasis. Based on the 
silhouette shading , a singlc investiga tor w ho had not eva luated these 
paticnts assigned a numeric va lue of 0 to 6 corrcsponding to 0 to '100'% 
involvement fo r each of the fo llowing fo ur areas: head. upper extrcmities, 
trunk . and lower extl"CI11itics. Equation 1 denlonstratcs o ur calculation 
method : 
SAPASI = [(0. 1 . AN) + (0.2 ' A u) + (0 .3' AT) 
[
4 . (VASE + VASt + VASs)] 
+ (0.4 . Aa] , 
VAS fells t" 
w h ere 
AH = H ead a rea score; 
Au = Upper extremi ty area score; 
AT = Trunk area score; 
AL = Lower extremities score; 
VAS = Visua l an alog sca le; 
VASE = VAS e ryth em a score (ml11); 
VASt = VAS induration score (111m) ; 
VASs = VAS scale score (mm). 
(I) 
O n the same day th at the patient cOl11p leted th e instrume n t, one 
of three clinicians blind to the SAP AS I rati n g obtained a PAS) 
score. T h e raters included the D irector (Dr. Feldman) and the 
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Coord inator (A. Clark, PA-C) of the Psoriasis T reatment Center, 
and a senio r resident in dermatology. T he investigators did not train 
the patients or teB them how they were doing prior to completion 
of the in strument. T he extent of involvement of each body area was 
scored 011 a 1 to 6 sca le . Each area was also ass igned a 0 to 4 
numeric score corresponding to "none," "sligh t," "moderate," 
"severe," and "extraordimu·jly severe" for erythema, infi ltration, 
and desquamation. 
A total of80 subjects (38 men, 42 women) had 153 paired PAS] 
and SAPASI observations. To evalu ate test-retest reliability of the 
SAPAS!, 19 of these subjects had I'epeated observations w ithin 2 d. 
To evaluate the responsiveness of the SAPASI to change in severity, 
we ana lyzed the 38 su bj ects that had repeated paired observations. 
In addition to the comparison between the full SAPAS! and the 
traditional PASl, the subcomponents of BSA, erythema, sca le, and 
induration, were compared between instruments. T his is a straight-
forward procedure for BSA since the SAPAS ! and PAS! m easure 
BSA on the same scale. T his is not the case for erythema, scale , and 
induration because the SAPAS! detemlines these for an "average 
lesion" and the PASl m easures erythema, sca le, and induration 
independently in each of the four body regions. To compare these 
components, the SAPAS! values were compared with computed 
PAS! averages. To compute an average erythem a, induration, o r 
scale score from the PAS! data, the individual scores for each area 
were averaged after weigh ting by the area of the body region and 
the percen tage area of involvement of that body region. T he PASl 
percentage area scores are recorded on an o rdinal sca le . For the 
purpose of calculating an average score, the midpoint of the 
corresponding inte rva l was chosen to represent the ordinal severity 
score. Equation 2 demonstrates this calcu lation for induration (Ix 
represents site specific induration for the head [H], upper extrem-
ities [U], trunk (11, and lower extremities [L]) : 
AI/crage illdurafioll = (0 .1 . AN . hi) + (0.2 . A u . l u) 
+ (0.3 . A-r . IT) + (0.4 . AL . IL). (2) 
To assess reproducibiljty of SAPASJ BSA measurements, flve 
raters-two dermatologists, a physic ian-assistant working in der-
. matology, an d two psychologist-blindly evaluated 40 body sil-
houettes randomly chosen from the 153 SAPASl observations. 
Separate BSA estim ates were made fo r the head, upper extremities, 
trunk, and lower extremities. From area estimates an overall BSA 
score was calcu lated (Equation 3) : 
BSA = (0 .1 . AN + 0.2 . A u + 0.3 . AT + 0.4 . AJ. (3) 
Using values generated by the SAS General Linear Models 
procedure, the intraclass correlation coefticient of re liability, It, was 
calculated according to the m e thod of Fleiss [4]. R values above 
0.75 represent excellent reliabili ty . For all other co mparisons, 
unless o therwise specified, statistica l significa nce was determined 
using Pearson's correlation. All data processing and statistical 
analysis were performed with the SAS system (Cary, NC). 
RESULTS 
The SAP ASI Is a Valid Measure of the Severity of Psoriasis 
Criterion validi ty refers to how a m easure compares with a "gold 
standard ." To evaluate criterion validity, SAPASI measurements 
were compared with PAS! scores. We further evaluated the ctiterion 
validi ty of each of the subcomponents of the SAPAS! by compating 
the SAPAS! nSA score with the PASI BSA score and the SAPAS! 
erythema, scale, and induration scores with cOITesponding averages 
calculated &om PAS! measurements. 
SAPAS] scores prcdict PASI scores: 'We perform ed lin ear regression 
for investigato r PAS! on SAPAST for the first observation (n = 80). 
Investigator PAS) had a signifi cant regression on SAPAS) (p < 
0.0001) and 59% oftbe variation in in vestigator PASt was explained 
(Fig 1). 
SAPASI BSA scores predict PASI BSA scores: U sing data from all 
subjects, (n = 80), signi ficant correla tio ns (all p = 0.000 1) were 
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Figure 1. Self-administered psoriasis area severity index (SAPASi) 
scores predict psoriasis area severity index (PASI) scores. T he first 
SAPASI and PASI scores obtained from 80 subjects were compared. 
Subsequent obse rvations on these subjects are not included in titis compar-
ison to prevent bias from multiple observations o n the salli e individual. 
Li.near regress io n and 95o/tJ confiden ce intervals arc shown. 
found between SA PASI and PASI for the following BSA determi-
nations: head area (r = 0.62), upper extremity area (r = 0.75) , 
trunk area (r = 0.73), lower extremity area (r = 0.69). Separate 
analyses were performed for men and women, and these results 
were also signifi can tl y correlated (all p < 0.0 '1). Men and women 
respectively had the following correla tio n coefricients: head area 
(r = 0.43 , r = 0 .74), upper extremity area (r = 0.74, r "" 0.78) , 
trunk area (r = 0.70, r = 0 .78), lower extremity (r = 0.71, r = 
0.68) . Area-wide estimates of disease involvement appear to be 
quite valid. 
SAPAS] CI)It/lCIl/ a, il/dllrnfioll, (II/{I sen Ie scores nficef PASI scorcs: W e 
compared the average erythem a, i.nduration and scale fi-om the 
SAPASI with computed average PAS! severity measures. Signifi-
cant but modest correlations were fo und for erythema (r =' 0.3 9, 
P = 0 .0003), i.nduration (r = 0.24, P = 0.03), and scale (r = 0.38, 
P = 0.0003) . Separatin g the subjects by gender, severity correla-
tions for men and wom en respectively were as fo ll ows: erythema (r 
= 0.31, P = 0.05; r = 0.46, P = 0.001), induration (r = 0.42, P =' 
0.008; r = 0 .09, P = 0.6), and scale (r = 0.33, P = 0.04; r =' 0.46, 
P = 0.002). T hus, w hen specific characteristics of lesions were 
compared between measures, correlation coefficients are substan-
tially lower, suggesting poorer validity. 
Because SAPASl induration was less strongly correlated with 
PAS! induration than other measures, we analyzed the first obser-
vation fi:om each individua l (n = 80) with and without induration 
to assess the impact of this va riable. Altho ugh linear I'egressions of 
SAPASl on PAS! with and w ith o ut induratio n were h.ighly signif-
icant (p = 0.0001), an F test for the contributi on of induration 
showed that tlus variable made a significant contribution to the 
regression (p < 0.0001) . T his latter finding suggests induration 
contributes predictive ability to the equation . 
The SAPASI Exhibits Test-Retest a nd Inter-Rater Reliabil-
ity Reliability is the exten t to w hich a measure yie lds the same 
score each time, aU other things being equal. To assess the re-
producibiljty of patient responses to the SAPAS!, subjects completed 
the SAPASI instrument twice over a short interva l. T he interval time 
was chosen as a balance between two f.,cto rs. First, if the time period 
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was too short, subjects Inight be biased on the second SAPASr by their 
responses on the first SAPASI; they might remember how they 
responded and give the same response again. Second, if the interval 
was too long, there might be significant changes in the true severity of 
the subjects' skin les ions biasing the results. An interval of 2 d was 
chosen to minimize both changes in pSOI;asis and m emory bias. 
Nineteen subjects completed a second pair PASI-SAPASI within 2 d of 
tIle index assessment. Sb~ong correlations were found between PASl 
scores over time (I' = 0.91, P = 0.0001) and SAPASI scores over time 
(r = 0.82, p = 0.0001). We also found moderate to strong con~elations 
for same-day ratings between first PASI and SAPASl (r = 0.58, p = 
0.009) and tIle second PAS! and SAPASl (I' = 0.70, P = 0.008) 
evaluations. 
A second re liability consideration is whether the instrument is 
scored by the investigator in a reproducible manner. Little variation 
is expected in scoring of the visual analog sca les since they are 
objectively measured directly with a rul er. Variation could occur 
with the more subjective scoring ofBSA. To assess reproducibility 
of scoring the BSA m eas urements on the SAPAST, five raters 
eva luated 40 body si lhouettes. Comparison of all t'aters found the 
BSA estimate intraclass correlation coefficient of reliability R = 
0.953. Individual body area comparisons were as follows: head 
(R = 0.962), upper extremi ty (R = 0.944), trunk (It = 0.939) , 
lower eXb'emities (R = 0.84). We also compared evaluator groups 
by their experience . Dermatologist and nondermatologist estimates 
ofBSA received a comparison R = 0.953, whereas individual body 
area R va lues ranged fi'olll 0.84 to 0.96 . 
The SAPASI is Responsive to Changes in Severity Respon-
siveness is the ability of a measure to reflect unde rlyin g change. To 
evaluate the responsiveness of the SAPAS I to change in clinical 
status, we exa mined chan ges of the SAPASI score over time. 
Changes in the PAST score were used to assess true changes in 
disease over time. We compared the first two paired SAPASIIPASI 
observations of 30 subjects whose observations were at least 2 d 
apart. Only the first two paired observations were used to prevent 
biases incurred from multipl e observations on the same subjects. 
Correlation of the difference between the first and second PAS! and 
SAPASI o bservations found a sign ifi cant correlation (1' = 0.63, P = 
0.0002). T hese results suggest that the SAPASI varies in parallel 
w ith the PAS!. As a further test of this parallel t'e lationship , we 
compared the mean diJference between SAPASl and PAS] over 
time. T he mean difFerence between the first PASI and SAPASl 
scores was -3.47 ± 6.46 and the second was - 2.50 ± 8.5. A t test 
fo und no signifi cant difFerence between these m eans (p = 0.22). 
We also wished to assess whether pati ents' ability to use tIle 
SAP AS] improves with multiple uses of the instrum ent; that is. docs 
the SAPASI become a better predictor of the PAS) over time (or 
with the "training" of havin g used the instrument multiple times). 
We analyzed PAST-SAPASl differences for all subjects and all 
observations. For each individual, a mean difference was calculated. 
The intersubject m ean difFerence was (mean ± SD) -2.25 ± 6.36. 
Using a repeated measures analysis of variance that takes into 
accolmt variability within and between indiv iduals, we investigated 
w hether there were changes in the difFerence between the PAST and 
SAPAS I over tim e. We found no significant trend (p = 0.2). 
DISCUSSION 
Developing and validating measures is becoming in creasingly im-
porta nt in clinical and epidemiologic research in dermatology. Skill 
disease can be measured in a number of ways including disabi.lity , 
social stigmatization , patient satisfaction, musculoskeletal morbid-
ity, and the severity of ski n involvement. We have developed the 
SAPASI to provide patients a means for objectively reporting the 
severity of psoriasis. The high corre\;ltion with the PASl score 
observed in this sample does imply that statistical inferences with 
the SAPASI will be valid for large popu lations. In future studies, 
this wi]1 permit an alysis of the relationship of psoriasis to such 
measures as disabi li ty. patient satisfaction, and the costs of various 
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therapies. Rigorous evaluation of the SAPAS! instrument is essen-
tial, however, be fore we may advocate widespread use. 
This study was d es igned to dete rmine if the SAPAST is suitable 
for making statistical inferences on the severity of psoriasis in 
populations. We have observed that, while there was excellent 
corre lation between the PAST and the SAPASI across tlte broad 
range of sevedty tested, for any given PAS I score there was a wide 
range of corresponding SAPASI scores. T hus, tbe APASI score 
may not accurately determine the sevcl;ty of psoriasis in some 
individual patients. Neverthe less, it may be possible to lISe the 
SAPASI to categorize patients in to classes of mild, moderate. and 
severe psoriasis. This wi ll require further investiga tion into the 
specific ity and sensitivity of scoring the SAP AS) in categories and is 
beyond the scope of the investigation reported here. 
The correlation between the SAPAS) and PASI demonstrates 
that the SAPASI is an excellent predic tor of severity. Separating the 
SAPASI into its component parts, w e also found that body sltl'f.'lce 
area, color, induration, and scale m easures are significantly con'e-
lated with the clinician-t'a ted PAS!. An interesting exception to th is 
was found in the evalu ation of induration in wo.men, in which no 
correla tion was found with i.nvestigator scores. Induration may be 
particularly challenging for untrained observers to reliably assess. 
Despite this finding, including duration in the SAPAS! does 
contribute va luable predictive pO\vel'. 
Eva luating tIle criterion va lidity of the SAPAS) remains problem-
atic, however, because there is no well-established "gold standard" 
for the severity of psoria sis. Because of its long history and 
widespread usc, the PAS! remains the most validated measltl'e of 
psoriasis. Staberg and Klemp found that skin blood flow in psoriasis 
during Goeckerm an or beech tar therapy had a significant linear 
correlation with the psoriasis index which takes into account 
infil tration, erythema, and sca ling (12]. Bakhtian found that trans-
epidermal water loss and chro m3meter b sca le parameters con'e-
la ted well with lesion scores. t Nevertheless, previous studies using 
clinicians of limited or varying degrees of expertise suggest that 
PAS I BSA estimates may not be accurate [10,11,13]. [n our studies . 
we e mployed on ly trained, experienced clinicians specializiJlg ill 
psoriasis to perform PAS! assessments. I t has recently been reported 
that observet- training may improve BSA assessment accuracy [1 3]. 
Thus, we believe our assessments by trained personnel make our 
PAS I assessments more re li ab le than previously reported assess-
ments by untrained personnel. 
T he reliability v f the SAPASI is supported by tlle test-retest 
re liabili ty demonstrated within 2 d . We do not expect severity to 
change markedly in this narrow time fi·am e. We also observed the 
ability of raters to estimate affected area £i'om subjects' nSA 
drawings . T hi s assessment suggests that scoring of the instrument is 
reliabl e with both trained and untrained raters. 
A clinical measure of disease has little utility if it can tlot reflect a 
change in status. By studying difFerences betwee n the PA I and 
SAPASI, we found that the SAPAS] varied in parallel with the 
PAS\. T his suggests t!tat the SAPASI is at least as robust as the PASI 
in monitol'ing responsiveness. 
One limitation of this study is that all the subj ects were patients 
at a single center (the Bowman Gray School of Medicine Psoriasis 
Treatment Center). A multicenter tria l using the instrument wou ld 
provide further evidence of its general va lid ity . Nevertheless . the 
simplicity of th e o ne-page instrument. the lack of need for any 
patient training, the wide variety of patients seen in our center, and 
the reproducible SCOriJlg of the SAPASI support the general validity 
of the instrument. 
T he PAS I score and ou r SAPAS I do not assess all aspects of 
psoriasis. Disabili ty, socia l stigmatization, and musculoskeleta l 
morbidity arc key aspects of psoriasis and are not m easured by the 
PAS I. Methods for quantifYin g these varia bl es are being developed 
I Uakhtian S. Pershing LK . Poncelet CEo Rallis TM: Objective nonin va-
sive and subjective v-isuai aSSCSSIl1Cllts of psoriasis and their li se in biocq lliva-
Icnee testing or topical O.05'Y" bctalllethasonc diproprionatc . .II"i/cst Demln-
'0/ ·100:540. 1993 (abst.) 
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[6]. W e have demonstrated that a population of patients can 
accura te ly assess their psoriasis in a valid and reproducible fashion 
using the SAP AS I. Additional research usin g the SAPASI can 
explore the re lationship between psoriasis and health-re lated qual-
ity of li fe. 
T ltis 1I'0rk lIIas sII pported by the N atiollal fllstitllte q{ Melltal Healtlt (gra llt IIl1/llber 
MH-5 1552). HIe tlt nll" pnst 'll e/llbers '!ft lt" lllterdisciplillnry S"ill Disease Reset/relt 
Gro llP, Jill Va llnl1/lOs, PA-C alii! S tcI'ell Cra ig, M.D. Jor Ilteir COlltriblltiollS. 
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